Study Title and Description
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.
Key Questions Addressed
|6||Key Question 6. What is the effectiveness of currently recommended antiviral treatments in improving health outcomes in patients with HCV infection?|
|7||Key Question 7. What is the effectiveness of currently recommended antiviral treatments in achieving a SVR in patients with HCV infection?|
|8||Key Question 8. What are the harms of currently recommended antiviral treatments?|
Primary Publication Information
|Title||Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.|
|Author||Foster GR., Afdhal N., Roberts SK., Bräu N., Gane EJ., Pianko S., Lawitz E., Thompson A., Shiffman ML., Cooper C., Towner WJ., Conway B., Ruane P., Bourlière M., Asselah T., Berg T., Zeuzem S., Rosenberg W., Agarwal K., Stedman CA., Mo H., Dvory-Sobol H., Han L., Wang J., McNally J., Osinusi A., Brainard DM., McHutchison JG., Mazzotta F., Tran TT., Gordon SC., Patel K., Reau N., Mangia A., Sulkowski M.|
|Country||From Queen Mary University of London (G.R.F.), University College London (W.R.), King's College Hospital (W.R.), and Institute of Liver Studies (K.A.) - all in London; Beth Israel Deaconess Medical Center, Boston (N.A.); Alfred Health and Monash University (S.K.R.) and St. Vincent's Hospital (A.T.), Melbourne, VIC, and Monash Health and Monash University, Clayton, VIC (S.P.) - all in Australia; James J. Peters Veterans Affairs Medical Center, Bronx (N.B.), and Icahn School of Medicine at Mount Sinai, New York (N.B.) - both in New York; Auckland Clinical Studies, Auckland (E.J.G.), and Christchurch Clinical Studies Trust and University of Otago, Christchurch (C.A.M.S.) - both in New Zealand; Texas Liver Institute, University of Texas Health Science Center, San Antonio (E.L.); Liver Institute of Virginia, Richmond (M.L.S.); University of Ottawa, Ottawa (C.C.), and Vancouver Infectious Diseases Centre, Vancouver, BC (B.C.) - both in Canada; Kaiser Permanente (W.J.T.), Ruane Medical (P.R.), and Cedars-Sinai Medical Center (T.T.T.), Los Angeles, and Gilead Sciences, Foster City (H.M., H.D.-S., L.H., J.W., J.M., A.O., D.M.B., J.G.M.) - all in California; Hôpital Saint Joseph, Marseilles (M.B.), and Service d'Hépatologie, Hôpital Beaujon, INSERM UMR 1149, Université Paris Diderot, Clichy (T.A.) - both in France; University Hospital Leipzig, Leipzig (T.B.), and Johann Wolfgang Goethe University, Frankfurt (S.Z.) - both in Germany; Santa Maria Annunziata Hospital, Florence (F.M.), and Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo (A.M.) - both in Italy; Henry Ford Health System, Detroit (S.C.G.); Duke University School of Medicine, Durham, NC (K.P.); Rush University Medical Center, Chicago (N.R.); and Johns Hopkins University, Baltimore (M.S.).|
Pubmed ID: 26575258
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Key Questions 1-9
Results & Comparisons
No Results found.